The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | EVOKE-02: sacituzumab govitecan and pembrolizumab in first-line NSCLC
Byoung Chul Cho, MD, PhD, Yonsei University College of Medicine, Seoul, South Korea, provides an overview of findings from the Phase II EVOKE-02 trial (NCT05186974) of sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate (ADC), and pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Patients were divided into two cohorts, where cohort A consisted of patients with a PD-L1 tumor proportion score (TPS) of more than 50%, and cohort B consisted of patients with a PD-L1 TPS of less than 50%. The investigational regimen showed promising safety and efficacy in both cohorts, and a higher overall response rate was observed in cohort A. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
